3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
12
Unknown
5
Terminated
3
Recruiting
3
Withdrawn
1
Suspended
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Sarcoma
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasm Metastasis
2
Leukemia, Myeloid, Acute
2
Carcinoma, Hepatocellular
2
Advanced Solid Tumors
2
Advanced Endometrial Cancer
2
Thrombosis
1
Thrombophilia
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Resectable Esophageal Squamous Cell Carcinoma
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Nasopharyngeal Neoplasms
1
Multiple Myeloma
1
Metastatic Solid Tumors
1
Melanoma
1
Interventions
Exercise
9
Standard of Care
5
trametinib
3
tislelizumab
3
Radiotherapy
3
Radiosurgery
3
Palliative Care
3
Paclitaxel
3
Gemcitabine
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
trastuzumab deruxtecan
2
cemiplimab
2
Therapeutics
2
Surveys and Questionnaires
2
Resistance Training
2
Oxaliplatin
2
Maintenance
2
Immune Checkpoint Inhibitors
2
Drug Therapy
2
Cisplatin
2
Anastrozole
2
vedolizumab
1
toripalimab
1
surufatinib
1
sparsentan
1
sintilimab
1
semaglutide
1
posaconazole
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Neoplasms
×
Injections
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled